CPS1 (P31327) variants and mutations
CPS1 (also known as P31327) is a human protein-coding gene encoding a carbamoyl-phosphate synthase [ammonia], mitochondrial protein. It catalyzes the first committed step of the hepatic urea cycle, incorporating ammonia into carbamoyl phosphate within mitochondria. Biallelic loss-of-function variants cause carbamoyl-phosphate synthetase I deficiency, which can produce life-threatening hyperammonemia. This analysis covers 2,597 CPS1 variants and mutations. Of these, 64% have computational variant effect predictions. Disease context includes carbamoyl phosphate synthetase I deficiency disease, Abnormality of the skeletal system, and Hyperammonemia. Example CPS1 variants include T2A, T2M, and T2T.
Variant analysis overview
- Gene: CPS1
- Protein: P31327
- UniProt accession: P31327
- Organism: Homo sapiens
- Variants analyzed: 2597
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 2,424 unspecified-consequence records; 88 missense variants; 5 splice-region variants; 2 in-frame insertions; 68 synonymous variants; 6 frameshift variants; 1 splice acceptor variant; 2 stop-gained variants; 1 substitution
- Prediction scores: 1,667 variants have prediction scores (64% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: carbamoyl phosphate synthetase I deficiency disease, Abnormality of the skeletal system, Hyperammonemia, venous thromboembolism, kidney failure, chronic kidney disease, hereditary disease, macular telangiectasia type 2, pulmonary arterial hypertension, inborn disorder of amino acid metabolism, alcohol drinking, Headache.
Protein structure and variant hotspots
- Protein features: 4 domains; 6 binding sites; 156 post-translational modification sites.
- Structural context: 1,156 variants have structural context.
- PTM context: 124 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CPS1 variants
Examples include T2A, T2M, T2T, R3K, R3M, R3R, I4M, I4S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- T2A (p.Thr2Ala), cosmic curated COSV10875
- T2M (p.Thr2Met), rs150314086, ClinGen CA2085922, ClinVar RCV000268597, ClinVar RCV000523694, REVEL 0.42, CADD 23.60, Conflicting interpretations, Inborn genetic diseases; not provided; Congenital hyperammonemia, type I
- T2T (p.Thr2Thr), rs374246990, gnomAD 2-210556739-G-A, CADD 8.68
- R3K (p.Arg3Lys), rs750705469, ExAC rs750705469, gnomAD rs750705469, AlphaMissense 0.42, MetaLR 0.88, Uncertain significance
- R3M (p.Arg3Met), rs750705469, ClinGen CA2085924, ClinVar RCV002019673, ExAC rs750705469, REVEL 0.64, AlphaMissense 0.42, Uncertain significance, Congenital hyperammonemia, type I
- R3R (p.Arg3Arg), rs2106037152, gnomAD 2-210556742-G-A, CADD 11.10
- I4M (p.Ile4Met), cosmic curated COSV10585
- I4S (p.Ile4Ser), cosmic curated COSV51802
- I4T (p.Ile4Thr), ExAC rs773003468, gnomAD rs773003468, REVEL 0.55, CADD 25.20, Likely benign, Congenital hyperammonemia, type I
- p.Ile5 Lys6insPhe, rs61509952, gnomAD 2-210556728-A-ATC, CADD 15.40
- I4F (p.Ile4Phe), rs201874641, gnomAD 2-210556728-A-T, CADD 10.30
- I4I (p.Ile4Ile), rs768210605, gnomAD 2-210556730-C-A, CADD 8.86
- L5* (p.Leu5Ter), cosmic curated COSV51814
- L5F (p.Leu5Phe), rs1696924953, ClinGen CA350432183, ClinVar RCV001279817, Ensembl rs1696924953, AlphaMissense 0.14, MetaLR 0.92, Uncertain significance, Congenital hyperammonemia, type I
- T6I (p.Thr6Ile), rs144889339, ClinGen CA2085926, ClinVar RCV003871874, ESP rs144889339, REVEL 0.34, CADD 22.80, Likely benign, Congenital hyperammonemia, type I
- T6T (p.Thr6Thr), gnomAD 2-210556751-A-G, CADD 10.70
- A7P (p.Ala7Pro), gnomAD rs1189535504, REVEL 0.66, CADD 25.40
- A7L (p.Ala7Leu), gnomAD 2-210556750-CA-C, CADD 23.80
- A7V (p.Ala7Val), gnomAD 2-210556753-C-T, REVEL 0.41, CADD 19.40
- K9* (p.Lys9Ter), rs1553507167, ClinGen CA350432262, ClinVar RCV000673929, Ensembl rs1553507167, CADD 33.00, Pathogenic
- K9Q (p.Lys9Gln), gnomAD 2-210556731-A-C, CADD 23.10
- V11A (p.Val11Ala), TOPMed rs1429079893, gnomAD rs1429079893, REVEL 0.36, CADD 20.10
- V11L (p.Val11Leu), ExAC rs754467312, TOPMed rs754467312, gnomAD rs754467312, REVEL 0.33, CADD 22.70
- V11M (p.Val11Met), ExAC rs754467312, TOPMed rs754467312, gnomAD rs754467312, REVEL 0.30, CADD 23.00
- V11G (p.Val11Gly), gnomAD 2-210556765-T-G, REVEL 0.54, CADD 23.20
- V11V (p.Val11Val), gnomAD 2-210556766-G-T, CADD 9.84
- R12S (p.Arg12Ser), NCI-TCGA Cosmic COSV5180, cosmic curated COSV51802, NCI-TCGA Cosmic COSV9924, cosmic curated COSV99242, Variant assessed as somatic; moderate impact.
- R12K (p.Arg12Lys), gnomAD 2-210556768-G-A, REVEL 0.35, CADD 11.00
- T13K (p.Thr13Lys), cosmic curated COSV99028
- T13T (p.Thr13Thr), rs755098080, gnomAD 2-210556772-A-C, CADD 1.34
- L14P (p.Leu14Pro), ExAC rs765353730, TOPMed rs765353730, gnomAD rs765353730, REVEL 0.70, CADD 25.70
- L14V (p.Leu14Val), gnomAD 2-210556773-C-G, REVEL 0.40, CADD 13.60
- K15E (p.Lys15Glu), TOPMed rs1178139060, gnomAD rs1178139060, REVEL 0.54, CADD 23.30
- K15N (p.Lys15Asn), gnomAD 2-210556778-G-T, REVEL 0.38, CADD 23.20
- K15K (p.Lys15Lys), rs1391510696, gnomAD 2-210556778-G-A, CADD 10.10
- T16N (p.Thr16Asn), Ensembl rs1696926576, REVEL 0.36, CADD 10.70, Uncertain significance, Congenital hyperammonemia, type I
- T16P (p.Thr16Pro), TOPMed rs1400264761, gnomAD rs1400264761, REVEL 0.42, CADD 15.30
- T16S (p.Thr16Ser), TOPMed rs1400264761, gnomAD rs1400264761, REVEL 0.33, CADD 10.60
- G17S (p.Gly17Ser), rs868808195, ClinGen CA64746652, ClinVar RCV002050403, ClinVar RCV005925722, REVEL 0.31, CADD 22.60, Conflicting interpretations, Congenital hyperammonemia, type I; not specified
- G19S (p.Gly19Ser), gnomAD rs1696926771, REVEL 0.32, CADD 15.00
- G19V (p.Gly19Val), gnomAD 2-210556789-G-T, REVEL 0.38, CADD 19.10
- F20L (p.Phe20Leu), TOPMed rs1391034796, gnomAD rs1391034796, REVEL 0.35, CADD 13.40
- F20I (p.Phe20Ile), gnomAD 2-210556791-T-A, REVEL 0.32, CADD 15.00
- T21N (p.Thr21Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T21P (p.Thr21Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N22D (p.Asn22Asp), TOPMed rs1696926949, gnomAD rs1696926949, REVEL 0.26, CADD 16.90
- N22H (p.Asn22His), TOPMed rs1696926949, gnomAD rs1696926949
- N22S (p.Asn22Ser), Ensembl rs1696927100, REVEL 0.24, CADD 12.70
- N22N (p.Asn22Asn), rs2106037321, gnomAD 2-210556799-T-C, CADD 4.31
- V23M (p.Val23Met), gnomAD 2-210556800-G-A, REVEL 0.21, CADD 20.80
- V23V (p.Val23Val), rs1696927192, gnomAD 2-210556802-G-A, CADD 8.02
- T24A (p.Thr24Ala), rs752849933, ClinGen CA2085930, ClinVar RCV003195439, ExAC rs752849933, REVEL 0.34, CADD 10.60, Uncertain significance, Inborn genetic diseases
- T24I (p.Thr24Ile), TOPMed rs760541781, gnomAD rs760541781, REVEL 0.31, CADD 14.00
- A25E (p.Ala25Glu), rs149570645, ClinGen CA2085931, ClinVar RCV002283302, ClinVar RCV003096356, REVEL 0.41, CADD 16.60, Conflicting interpretations, not provided; Inborn genetic diseases; Congenital hyperammonemia, type I
- A25T (p.Ala25Thr), cosmic curated COSV51821, REVEL 0.31, CADD 15.80
- A25V (p.Ala25Val), rs149570645, ClinGen CA2085932, ClinVar RCV001373549, 1000Genomes rs149570645, REVEL 0.32, CADD 17.60, Likely benign, Congenital hyperammonemia, type I
- H26N (p.His26Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H26Y (p.His26Tyr), gnomAD 2-210556809-C-T, REVEL 0.27, CADD 4.76
- H26H (p.His26His), rs745616278, gnomAD 2-210556811-C-T, CADD 2.85
- Q27* (p.Gln27Ter), rs2469040081, ClinGen CA350432704, ClinVar RCV003468541, Likely pathogenic
- Q27K (p.Gln27Lys), cosmic curated COSV51815
- Q27R (p.Gln27Arg), rs1279373364, gnomAD rs1279373364, REVEL 0.31, CADD 7.69, Variant assessed as somatic; moderate impact.
- Q27E (p.Gln27Glu), rs1230411824, gnomAD 2-210556722-C-G, CADD 2.69
- p.Gln3 Ile4insVal, gnomAD 2-210556724-A-AGT, CADD 10.50
- Q27H (p.Gln27His), gnomAD 2-210556724-A-T, CADD 16.60
- K28N (p.Lys28Asn), NCI-TCGA TCGA novel, 1000Genomes rs574128765, ExAC rs574128765, TOPMed rs574128765, Likely benign
- K28K (p.Lys28Lys), rs574128765, gnomAD 2-210556817-A-G, CADD 6.87
- W29* (p.Trp29Ter), rs2469040102, NCI-TCGA Cosmic COSV5180, cosmic curated COSV51803, ClinGen CA350432767, CADD 36.00, Likely pathogenic
- W29L (p.Trp29Leu), gnomAD 2-210556819-G-T, REVEL 0.49, CADD 22.90
- W29C (p.Trp29Cys), gnomAD 2-210556820-G-T, REVEL 0.53, CADD 23.10
- K30E (p.Lys30Glu), Ensembl rs2106037369
- F31I (p.Phe31Ile), NCI-TCGA Cosmic COSV5182, cosmic curated COSV51826, Variant assessed as somatic; moderate impact.
- F31Y (p.Phe31Tyr), gnomAD rs1356416457
- S32* (p.Ser32Ter), cosmic curated COSV51827
- S32L (p.Ser32Leu), cosmic curated COSV10508, REVEL 0.44, CADD 21.10
- S32P (p.Ser32Pro), gnomAD 2-210556827-T-C, REVEL 0.55, CADD 21.40
- P34H (p.Pro34His), gnomAD rs1203974161, REVEL 0.33, CADD 18.50
- P34L (p.Pro34Leu), gnomAD 2-210556720-C-T, CADD 13.40
- P34P (p.Pro34Pro), gnomAD 2-210556721-A-G, CADD 7.39
- P34S (p.Pro34Ser), gnomAD 2-210556833-C-T, REVEL 0.27, CADD 16.40
- G35D (p.Gly35Asp), rs1574520391, ClinGen CA350432873, ClinVar RCV000797807, Ensembl rs1574520391, AlphaMissense 0.15, MetaLR 0.83, Uncertain significance, Congenital hyperammonemia, type I
- G35S (p.Gly35Ser), cosmic curated COSV51804, gnomAD rs1696928131, REVEL 0.26, CADD 21.30
- G35G (p.Gly35Gly), gnomAD 2-210556838-C-T, CADD 9.56
- I36T (p.Ile36Thr), TOPMed rs976040223, gnomAD rs976040223, REVEL 0.37, CADD 15.80
- I36V (p.Ile36Val), Ensembl rs1559074882, REVEL 0.30, CADD 11.80
- I36L (p.Ile36Leu), gnomAD 2-210556839-A-C, REVEL 0.41, CADD 14.00
- R37M (p.Arg37Met), NCI-TCGA Cosmic COSV5180, cosmic curated COSV51808, Variant assessed as somatic; moderate impact.
- R37S (p.Arg37Ser), ExAC rs779953205, gnomAD rs779953205, REVEL 0.53, CADD 16.30
- R37R (p.Arg37Arg), rs1265700144, gnomAD 2-210556842-A-C, CADD 8.28
- L38F (p.Leu38Phe), rs749164722, ClinGen CA2085936, ClinVar RCV001142800, ExAC rs749164722, REVEL 0.44, CADD 18.00, Uncertain significance, Congenital hyperammonemia, type I
- L38P (p.Leu38Pro), gnomAD 2-210556845-CT-C, CADD 24.10
- L39F (p.Leu39Phe), TOPMed rs1242900445, gnomAD rs1242900445, REVEL 0.36, CADD 15.20
- L39H (p.Leu39His), gnomAD rs1422483042, REVEL 0.58, CADD 23.00
- L39I (p.Leu39Ile), TOPMed rs1242900445, gnomAD rs1242900445, REVEL 0.31, CADD 15.80
- L39P (p.Leu39Pro), gnomAD 2-210556849-T-C, REVEL 0.58, CADD 24.20
- S40F (p.Ser40Phe), ExAC rs768584680, gnomAD rs768584680, REVEL 0.63, CADD 22.90
- S40S (p.Ser40Ser), gnomAD 2-210556853-T-C, CADD 7.89
- V41A (p.Val41Ala), TOPMed rs1696929292
- V41F (p.Val41Phe), rs148708735, ClinGen CA2085938, ClinVar RCV000803314, ClinVar RCV003258979, REVEL 0.51, CADD 22.80, Conflicting interpretations, Inborn genetic diseases; Congenital hyperammonemia, type I
- K42=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- K42R (p.Lys42Arg), gnomAD rs1470087353, REVEL 0.35, CADD 24.70
- K42N (p.Lys42Asn), gnomAD 2-210556859-G-C, REVEL 0.51, CADD 32.00
- A43=, NCI-TCGA Cosmic COSV5181, Variant assessed as somatic; low impact., in CPS1D
- A43T (p.Ala43Thr), TOPMed rs1697578176, REVEL 0.46, CADD 24.00
- A43V (p.Ala43Val), UniProt VAR 066171, Pathogenic, in CPS1D
- p.Ala43 Gln44del, gnomAD 2-210573294-TCAGG, CADD 24.90
- Q44* (p.Gln44Ter), rs121912593, ClinGen CA115527, ClinVar RCV000002521, ClinVar RCV004566674, CADD 36.00, Pathogenic
- T45R (p.Thr45Arg), gnomAD 2-210573305-C-G, REVEL 0.74, CADD 21.40
- T45I (p.Thr45Ile), gnomAD 2-210573305-C-T, REVEL 0.54, CADD 22.70
- T45T (p.Thr45Thr), rs1414234472, gnomAD 2-210573306-A-G, CADD 9.69
- A46S (p.Ala46Ser), NCI-TCGA Cosmic COSV5181, Variant assessed as somatic; moderate impact.
- A46T (p.Ala46Thr), NCI-TCGA Cosmic COSV5181, cosmic curated COSV51813, Variant assessed as somatic; moderate impact.
- H47N (p.His47Asn), TOPMed rs1159264194, gnomAD rs1159264194, REVEL 0.26, CADD 18.30
- H47P (p.His47Pro), Ensembl rs1697578646
- H47Q (p.His47Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H47R (p.His47Arg), gnomAD 2-210573311-A-G, REVEL 0.32, CADD 20.30
- H47H (p.His47His), rs2106073214, gnomAD 2-210573312-C-T, CADD 9.18
- I48L (p.Ile48Leu), Ensembl rs1574540076, REVEL 0.24, CADD 16.40
- I48T (p.Ile48Thr), cosmic curated COSV10802, TOPMed rs1471219147, gnomAD rs1471219147, REVEL 0.84, CADD 24.10
- I48V (p.Ile48Val), NCI-TCGA TCGA novel, REVEL 0.38, CADD 22.30, Variant assessed as somatic; moderate impact.
- I48S (p.Ile48Ser), gnomAD 2-210573314-T-G, REVEL 0.91, CADD 24.90
- V49V (p.Val49Val), rs1574540092, gnomAD 2-210573318-C-T, CADD 9.96
- L50P (p.Leu50Pro), rs2469077959, ClinGen CA350421609, ClinVar RCV003110198, Likely pathogenic, Congenital hyperammonemia, type I
- L50V (p.Leu50Val), TOPMed rs1697579012
- L50L (p.Leu50Leu), rs182538050, gnomAD 2-210573321-G-A, CADD 9.83
- E51E (p.Glu51Glu), rs1231201792, gnomAD 2-210573324-A-G, CADD 11.80
- D52G (p.Asp52Gly), rs779756731, ClinGen CA2085952, ClinVar RCV001919560, ExAC rs779756731, REVEL 0.93, CADD 25.50, Uncertain significance, Congenital hyperammonemia, type I
- D52N (p.Asp52Asn), rs141481633, ClinGen CA2085951, ClinVar RCV001240876, ClinVar RCV001788431, REVEL 0.70, CADD 24.70, Conflicting interpretations, Inborn genetic diseases; not provided; Congenital hyperammonemia, type I
- G53* (p.Gly53Ter), cosmic curated COSV51821
- G53A (p.Gly53Ala), rs140092912, ClinGen CA2085953, ClinVar RCV000997654, ClinVar RCV002549977, REVEL 0.96, CADD 26.10, Uncertain significance, not provided; Inborn genetic diseases; Congenital hyperammonemia, type I
- G53E (p.Gly53Glu), ESP rs140092912, ExAC rs140092912, TOPMed rs140092912, gnomAD rs140092912, REVEL 0.96, CADD 27.20, Uncertain significance
- G53G (p.Gly53Gly), gnomAD 2-210573330-A-T, CADD 13.30
- T54I (p.Thr54Ile), ESP rs371343440, TOPMed rs371343440, gnomAD rs371343440, REVEL 0.77, CADD 24.30
- T54S (p.Thr54Ser), gnomAD 2-210573331-A-T, REVEL 0.60, CADD 19.10
- T54T (p.Thr54Thr), gnomAD 2-210573333-T-C, CADD 1.33
- K55* (p.Lys55Ter), cosmic curated COSV51809
- K55N (p.Lys55Asn), TOPMed rs1697579905
- K55T (p.Lys55Thr), gnomAD 2-210573335-A-C, REVEL 0.45, CADD 20.50
- M56I (p.Met56Ile), cosmic curated COSV10508
- M56R (p.Met56Arg), rs778958318, ClinGen CA312400, ClinVar RCV000667001, ClinVar RCV002271449, REVEL 0.91, CADD 24.00, Conflicting interpretations, Inborn genetic diseases; not provided; not specified
- M56V (p.Met56Val), gnomAD 2-210573337-A-G, REVEL 0.53, CADD 23.00
- M56T (p.Met56Thr), gnomAD 2-210573338-T-C, REVEL 0.89, CADD 23.40
- K57N (p.Lys57Asn), gnomAD rs1697580152, REVEL 0.36, CADD 18.50
- K57Q (p.Lys57Gln), gnomAD 2-210573340-A-C, REVEL 0.49, CADD 20.30
- K57K (p.Lys57Lys), gnomAD 2-210573342-A-G, CADD 9.49
- G58A (p.Gly58Ala), TOPMed rs1322797496
- G58D (p.Gly58Asp), UniProt VAR 066172, Pathogenic, in CPS1D
- G58V (p.Gly58Val), cosmic curated COSV10457
- G58S (p.Gly58Ser), gnomAD 2-210573343-G-A, REVEL 0.98, CADD 27.10
- G58G (p.Gly58Gly), rs1574540146, gnomAD 2-210573345-T-C, CADD 3.10
- Y59C (p.Tyr59Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y59Y (p.Tyr59Tyr), rs1390730716, gnomAD 2-210573348-C-T, CADD 7.86
- S60A (p.Ser60Ala), TOPMed rs1022147946, gnomAD rs1022147946, REVEL 0.85, CADD 24.20
- S60T (p.Ser60Thr), TOPMed rs1022147946, gnomAD rs1022147946, REVEL 0.92, CADD 25.60
- G62C (p.Gly62Cys), cosmic curated COSV10956
- G62D (p.Gly62Asp), cosmic curated COSV10437, REVEL 0.96, CADD 26.70
- G62S (p.Gly62Ser), gnomAD 2-210573355-G-A, REVEL 0.92, CADD 28.90
- G62G (p.Gly62Gly), rs529836556, gnomAD 2-210573357-C-T, CADD 10.10
- H63Q (p.His63Gln), NCI-TCGA Cosmic COSV5181, cosmic curated COSV51812, Variant assessed as somatic; moderate impact.
- P64Q (p.Pro64Gln), ExAC rs771683184, gnomAD rs771683184, REVEL 0.42, CADD 19.80
- P64P (p.Pro64Pro), rs772730335, gnomAD 2-210573363-A-G, CADD 9.86
- S65F (p.Ser65Phe), rs375979196, ClinGen CA2085959, ClinVar RCV002976729, UniProt VAR 066173, REVEL 0.66, CADD 23.10, Uncertain significance, Congenital hyperammonemia, type I
- S65S (p.Ser65Ser), rs192759073, gnomAD 2-210573366-C-T, CADD 11.00
- S66F (p.Ser66Phe), TOPMed rs1384532433, gnomAD rs1384532433, REVEL 0.75, CADD 24.00, Uncertain significance, not specified
- V67I (p.Val67Ile), gnomAD 2-210573370-G-A, REVEL 0.27, CADD 20.70
- A68V (p.Ala68Val), gnomAD 2-210573374-C-T, REVEL 0.71, CADD 22.50
- G69V (p.Gly69Val), ExAC rs777083560, gnomAD rs777083560, REVEL 0.99, CADD 27.00
- G69G (p.Gly69Gly), gnomAD 2-210573378-T-G, CADD 13.60
- E70K (p.Glu70Lys), cosmic curated COSV51806
- V71G (p.Val71Gly), UniProt VAR 066174, Pathogenic, in CPS1D
- V71M (p.Val71Met), TOPMed rs1256930702, gnomAD rs1256930702, REVEL 0.81, CADD 26.80
- V71L (p.Val71Leu), gnomAD 2-210573382-G-T, REVEL 0.42, CADD 22.30
- V72D (p.Val72Asp), gnomAD rs1339181885, REVEL 0.98, CADD 27.80
- V72I (p.Val72Ile), Ensembl rs1697582022, REVEL 0.69, CADD 23.80
- N74H (p.Asn74His), cosmic curated COSV51822
- N74I (p.Asn74Ile), NCI-TCGA Cosmic COSV5181, cosmic curated COSV51810, Variant assessed as somatic; moderate impact.
- N74S (p.Asn74Ser), rs1203626815, ClinGen CA350422217, ClinVar RCV003058997, gnomAD rs1203626815, REVEL 0.60, CADD 23.80, Uncertain significance, Congenital hyperammonemia, type I
- T75A (p.Thr75Ala), cosmic curated COSV51822
- T75N (p.Thr75Asn), ExAC rs760025125, gnomAD rs760025125, REVEL 0.91, CADD 25.30
- T75S (p.Thr75Ser), gnomAD 2-210573394-A-T, REVEL 0.95, CADD 25.80
Public CPS1 analysis runs
- CPS1 analysis run — CPS1 (2,597 variants) — completed 2026-08-19